Results 51 to 60 of about 14,435 (208)
The Journal of Clinical Pharmacology, Volume 66, Issue 4, April 2026.Abstract Labetalol is widely prescribed as a first‐line antihypertensive in pregnancy; however, rare but potentially severe idiosyncratic hepatotoxicity has been reported, with a disproportionately strong reporting signal for liver injury relative to other β‐blockers.
Emma D. Hendriksen +2 more
wiley +1 more source
Medical Journal of Australia, Volume 224, Issue 4, April 2026.ABSTRACT Objectives To evaluate the uptake of a new 60‐day dispensing policy for antihypertensive medicines and estimated cost savings compared with conventional 30‐day dispensing; and to explore general practitioner and pharmacist perspectives on the new policy.
Tian Wang +9 more
wiley +1 more source
Journal of the Formosan Medical Association, 2006 To evaluate the effect of pretreatment with the mixed alpha- and beta-adrenergic blocker, labetalol, on blood pressure instability during surgical resection of pheochromocytoma. Methods: Blood pressure stability and surgical results were compared between
Peter Chi-Ho Chung +4 more
doaj +1 more source
Adrenal pheochromocytoma incidentally discovered in a patient with parkinsonism [PDF]
, 2015 To evaluate the diagnostic route of pheochromocytoma (PHEO) in a patient under dopaminergic treatment. A 70-year-old man with Parkinsonism and under treatment with levodopa and carbidopa came to our observation for evaluation of arterial hypertension and
Claudio Letizia +7 more
core +1 more source
Health Science Reports, Volume 9, Issue 3, March 2026.ABSTRACT Background According to global projections, by the year 2050, ischemic heart disease will remain the leading cause of cardiovascular deaths with hypertension as a leading modifiable risk factor for mortality. Improving quality care for patients with acute myocardial infarction (MI) is associated with improved outcomes. Aims There is inadequate
Banaz Sadiq Elias +2 more
wiley +1 more source
Hypertension in Pregnancy, 2022 Objectives This network meta-analysis aimed to compare the efficacy and safety of intravenous (IV) hydralazine, oral nifedipine, and IV labetalol with different dosage regimens in the treatment of severe hypertension during pregnancy.
Hui-Zhen Wu +5 more
doaj +1 more source
Micro-RNA family that modulates fibrosis and uses thereof [PDF]
, 2017 The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response
Olson, Eric N., van Rooij, Eva
core +1 more source
A Facile Protocol for C(sp2)–C(sp3) Bond Formation Reactions Toward Functionalized E3 Ligase Ligands
ChemMedChem, Volume 21, Issue 4, 25 February 2026.A robust C(sp2)–C(sp3) decarboxylative coupling strategy enables access to new CRBN ligands and degraders with improved physicochemical properties. This synthetic approach is expanding the chemical space beyond C(sp2)–N linkages, fine‐tuning proteolysis‐targeting chimera activities and unlocking previously inaccessible degrader chemotypes.
Anita Maksutova +15 more
wiley +1 more source
Crystallization of apotransferrin derivatives with small chiral molecules [PDF]
, 2019 Transferin je protein krvne plazme koji se nalazi u skoro svim živim bićima i njegove su glavne funkcije transport i reguliranje količine željeza u krvi. Apotransferin je slobodan oblik proteina, onaj na koji nije vezano željezo.
Domin, Tea
core +1 more source
Micro-RNAS that control myosin expression and myofiber identity [PDF]
, 2015 The present invention relates to the identification of two microRNAs, miR-499 and miR-208b, that repress fast skeletal muscle contractile protein genes. Expression of miR-499 and/or miR-208b can be used to repress fast fiber genes and activate slow fiber
Olson, Eric N., van Rooij, Eva
core +1 more source